Lilly, BMS, and Incyte have each announced new AI‑focused deals to deepen artificial intelligence integration across drug discovery, development, and enterprise operations.
Bristol Myers Squibb (BMS) has struck a strategic agreement with Anthropic to deploy the Claude AI model across more than 30,000 employees, embedding it into research, clinical development, manufacturing, commercial, and corporate workflows.
Eli Lilly is integrating its AI engine Lilly TuneLab into Collaborative Drug Discovery’s CDD Vault, enabling biotechs to access Lilly’s proprietary data inside a secure data‑sharing environment.
Incyte has expanded its partnership with Genesis Molecular AI with a $120 million upfront package ($80 million cash plus $40 million equity) and potential milestone payments that could exceed $1 billion across five initial targets.
Sources:
Incyte inks deal with Edison to train AI through drug discovery
Eli Lilly to present at Bernstein's Strategic D... | Pluang
AI Opportunities in Pharma with Eli Lilly, AstraZeneca, & Bristol ...
Bristol Myers Squibb Enters Strategic Agreement with Anthropic ...
Eli Lilly inks $2.8B AI drug discovery deal
Incyte pays Genesis $80M to expand AI-fueled drug discovery pact
Factbox-Pharma sector doubles down on AI amid hopes of slashing ...
AI Is Changing Pharma's Bottom Line Now—But Not Through Splashy ...
Lilly, BMS, Incyte strike deals to keep biopharma's AI integration rolling
Bristol Myers deepens AI investment with Anthropic deal
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio | PharmExec